Multiple antigen specific cell therapy - HengRui YuanZheng Biotechnology
Alternative Names: Cytotoxic T-cell therapy - HengRui YuanZheng; Dendritic cell therapy - HengRui YuanZheng; MASCT I; MASCT-1; Multiple target antigen stimulating cell therapy-I; Multiple-antigen specific cell therapy-I; Neo-MASCTLatest Information Update: 22 Jul 2024
At a glance
- Originator HengRui YuanZheng Bio-Technology
- Developer Beijing Cancer Hospital; HengRui YuanZheng Bio-Technology; SYZ Cell Therapy
- Class Antineoplastics; Cell therapies; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants; Programmed cell death 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Urogenital cancer
- Phase I/II Solid tumours
- Phase I Liver cancer
- No development reported Gastric cancer
Most Recent Events
- 17 Jul 2024 HengRui YuanZheng Bio-Technology plans a phase I/II for Liver cancer in 2025 (HengRui YuanZheng Bio-Technology pipeline, July 2024).
- 29 Feb 2024 HengRui YuanZheng Bio-Technology plans a phase II trial for Soft tissue sarcoma (Metastatic disease, Late stage disease, Inoperable/Unresectable, Combination therapy, Recurrent, First line therapy) in China (parenteral) in February 2024 (NCT06277154)
- 01 Nov 2023 Phase-I clinical trials in Liver cancer (IV) prior to October 2023 (HengRui YuanZheng Bio-Technology pipeline, October 2023)